ID   SKBR3-AZDRb
AC   CVCL_EI05
DR   cancercelllines; CVCL_EI05
DR   Wikidata; Q54954665
RX   PubMed=26883193;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_132986; Sapitinib (AZD8931).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 12
//
RX   PubMed=26883193; DOI=10.18632/oncotarget.7317; PMCID=PMC4905492;
RA   Creedon, Helen
RA   Gomez-Cuadrado, Laura
RA   Tarnauskaite, Zygimante
RA   Balla, Jozef
RA   Canel, Marta
RA   MacLeod, Kenneth G.
RA   Serrels, Bryan
RA   Fraser, Craig
RA   Unciti-Broceta, Asier
RA   Tracey, Natasha
RA   Le Bihan, Thierry
RA   Klinowska, Teresa
RA   Sims, Andrew H.
RA   Byron, Adam
RA   Brunton, Valerie G.
RT   "Identification of novel pathways linking epithelial-to-mesenchymal
RT   transition with resistance to HER2-targeted therapy.";
RL   Oncotarget 7:11539-11552(2016).
//